Journal
ORAL ONCOLOGY
Volume 63, Issue -, Pages 44-51Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.oraloncology.2016.11.002
Keywords
Radiotherapy; Head and neck cancer; Head and neck squamous cell carcinoma; Radiation-sensitizing agents; Molecular targeted therapy; Radiation resistance; Radioresistance; DNA damage
Categories
Funding
- Wright Foundation
- Watt Family Foundation
Ask authors/readers for more resources
Radiation therapy plays an essential role in the treatment of head and neck squamous cell carcinoma (HNSCC), yet therapeutic efficacy is hindered by treatment-associated toxicity and tumor recurrence. In comparison to other cancers, innovation has proved challenging, with the epidermal growth factor receptor (EGFR) antibody cetuximab being the only new radiosensitizing agent approved by the FDA in over half a century. This review examines the physiological mechanisms that contribute to radioresistance in HNSCC as well as preclinical and clinical data regarding novel radiosensitizing agents, with an emphasis on those with highest translational promise. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available